Bio News

Bristol Myers Squibb (BMS) said its bispecific antibody-drug conjugate (ADC) iza-bren produced positive results in all five Phase 3 trials in China.
In the Phase 3 Panku-Lung01 trial in lung cancer, iza-bren reduced the risk of disease progression or death by 60% compared with platinum-based chemotherapy.
BMS said the results have increased its confidence in global Phase 3 trials.

Biobook Team
biobookmedia@biobook.co.krCosentyx Approved by FDA for 11th Indication: Polymyalgia Rheumatica
Delonix and Singapore’s A*STAR IDL to Collaborate on Vaccine Against Drug-Resistant Klebsiella pneumoniae
Brazilian Health Regulatory Agency Approves Oral Plaque Psoriasis Treatment Icotyde
Medtronic to Acquire Contego Medical for $380 Million
Brazilian Health Regulatory Agency Approves Botox for Masseter Muscle Prominence
Roche’s oral SERD Itovebi wins FDA approval, cutting risk of progression by 62%